Arranta Bio

About Arranta Bio

Arranta Bio is a dynamic player in the biotechnology sector, specifically focusing on the microbiome. The company operates as a contract development and manufacturing organization (CDMO), which means it helps other companies develop and manufacture their products. Arranta Bio was established in May 2019 and quickly expanded by merging with Captozyme, a seasoned CDMO with a decade of experience. This merger has strengthened Arranta Bio's capabilities, allowing it to support clients from the early stages of product development through to commercial manufacturing.

Arranta Bio serves a niche market of companies developing microbiome-related therapies. These therapies involve using live microorganisms to treat various health conditions. The company’s clients range from small biotech startups to large pharmaceutical companies. Arranta Bio provides a comprehensive suite of services, including process development, clinical supply production under current Good Manufacturing Practices (cGMP), and commercial manufacturing. This end-to-end service model ensures that clients can rely on Arranta Bio throughout the entire lifecycle of their product development.

The business model of Arranta Bio is service-based. It generates revenue by charging fees for its development and manufacturing services. These fees can be structured in various ways, including project-based fees, milestone payments, and long-term contracts. By offering specialized expertise and state-of-the-art facilities, Arranta Bio positions itself as a valuable partner for companies in the microbiome therapy space.

The company operates primarily in the United States, with facilities in Gainesville, Florida, and Watertown, Massachusetts. The team at Arranta Bio is composed of highly skilled professionals with extensive experience in microbiome therapy development and manufacturing. This expertise, combined with a strong commitment to quality and regulatory compliance, makes Arranta Bio a trusted partner in the industry.